Paper - WANFANG MED ONLINE

You Position: Home > Paper

Non-invasive tests of non-alcoholic fatty liver disease

( views:0, downloads:0 )

Author:: No author available

Journal Title:: Chinese Medical Journal

Issue:: 5

DOI:: 10.1097/CM9.0000000000002027

Key Word:: Fatty liver;Non-alcoholic fatty liver disease;Non-alcoholic steatohepatitis;Liver fibrosis;Cirrhosis;Transient elastography;FibroScan;Magnetic resonance imaging;Fatty liver;Non-alcoholic fatty liver disease;Non-alcoholic steatohepatitis;Liver fibrosis;Cirrhosis;Transient elastography;FibroScan;Magnetic resonan

Abstract： For the detection of steatosis, quantitative ultrasound imaging techniques have achieved great progress in past years. Magnetic resonance imaging proton density fat fraction is currently the most accurate test to detect hepatic steatosis. Some blood biomarkers correlate with non-alcoholic steatohepatitis, but the accuracy is modest. Regarding liver fibrosis, liver stiffness measurement by transient elastography (TE) has high accuracy and is widely used across the world. Magnetic resonance elastography is marginally better than TE but is limited by its cost and availability. Several blood biomarkers of fibrosis have been used in clinical trials and hold promise for selecting patients for treatment and monitoring treatment response. This article reviews new developments in the non-invasive assessment of non-alcoholic fatty liver disease (NAFLD). Accumulating evidence suggests that various non-invasive tests can be used to diagnose NAFLD, assess its severity, and predict the prognosis. Further studies are needed to determine the role of the tests as monitoring tools. We cannot overemphasize the importance of context in selecting appropriate tests.

Reference

[1]Marsman HA,van Werven JR,Smits NJ,etc.Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy.[J].2010,256(1).
[2]Parkes J,Roderick P,Harris S,etc.Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.[J].2010,59(9).
[3]Peter, Bannas,Harald, Kramer,Diego, Hernando,etc.Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers.[J].2015,62.
[4]Thierry Poynard,Vlad Ratziu,Sylvie Naveau,etc.The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis[J].2005,4(1).
[5]Guangqin Xiao,Sixian Zhu,Xiao Xiao,etc.Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis[J].2017,66(5).
[6]Vincent Wai-Sun, Wong,Grace Lai-Hung, Wong,Angel Mei-Ling, Chim,etc.Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis.[J].2008,103.
[7]Otgonsuren,M.,Younossi,Z.M.,Venkatesan,C.,etc.In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not[J].2013,62(3).
[8]Yu-Jie Zhou,Yi-Fan Zhou,Ji-Na Zheng,etc.NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver[J].2017,475.
[9]Cyrielle Caussy,Jun Chen,Mosab H. Alquiraish,etc.Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease[J].2018,16(12).
[10]Yu-Jie,Zhou,Fang-Zhou,Ye,Yang-Yang,Li,etc.Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.[J].2019,7(8).
[11]Anita Kiani,Vanessa Brun,Fabrice Lainé,etc.Acoustic radiation force impulse imaging for assessing liver fibrosis in alcoholic liver disease[J].2016,(20).
[12]Giorgio, Bedogni,Stefano, Bellentani,Lucia, Miglioli,etc.The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.[J].2006,6.
[13].3章Social Graphとレコメンドエンジンが導く「見えない関係性」[J].2008,2008(280).
[14]Orsak, Beverly,Maximos, Maryann,Lomonaco, Romina,etc.High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels[J].2015,100(6).
[15]Yu-Jie Zhou,Ji-Na Zheng,Wen-Yue Liu,etc.The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver[J].2017,468.
[16]Jeffrey GP,Ching HL,De Boer WB,etc.Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.[J].2011,26(10).
[17]Stefano, Romeo,Julia, Kozlitina,Chao, Xing,etc.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.[J].2008,40.
[18]Castera, Laurent,Friedrich-Rust, Mireen,Loomba, Rohit.Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease[J].2019,156(5).
[19]Oberti F,Deugnier Y,Moal V,etc.Comparison of blood tests for liver fibrosis specific or not to NAFLD.[J].2009,50(1).
[20]Eduardo Vilar-Gomez,Naga Chalasani.Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers[J].2018,68(2).
[21]Alexander R, Guimaraes,Luiz, Siqueira,Ritika, Uppal,etc.T2 relaxation time is related to liver fibrosis severity.[J].2016.
[22]Ruben Hernaez,Mariana Lazo,Susanne Bonekamp,etc.Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis[J].2011,54(3).
[23]Siddharth Singh,Alina M. Allen,Zhen Wang,etc.Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies[J].2014,13(4).
[24]Grace L‐H Wong,Vincent W‐S Wong,Paul C‐L Choi,etc.Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B[J].2009,24(6).
[25]Xinrong,Zhang,Grace Lai-Hung,Wong,Vincent Wai-Sun,Wong.Application of transient elastography in nonalcoholic fatty liver disease.[J].2020,26(2).
[26]Lazarus Jeffrey V.,Anstee Quentin M.,Hagström Hannes,etc.Defining comprehensive models of care for NAFLD[J].2021,18(10).
[27]Masahide, Hamaguchi,Takao, Kojima,Yoshito, Itoh,etc.The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation.[J].2007,102(12).
[28]Shaheen, AAM,Myers, RP.Diagnostic accuracy of the aspartate aminotransferaseto-platelet ratio index for the prediction of hepatitis c-related fibrosis: A systematic review[J].2007,46(3).
[29]Vincent Wai-Sun Wong,Shiv Chitturi,Grace Lai-Hung Wong,etc.Pathogenesis and novel treatment options for non-alcoholic steatohepatitis[J].2016,(1).
[30]Park, Charlie C.,Phirum Nguyen,Hernandez, Carolyn,etc.Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease[J].2017,152(3).
[31]McPherson, Stuart,Hardy, Tim,Dufour, Jean-Francois,etc.Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis[J].2017,112(5).
[32]Richard K, Sterling,Eduardo, Lissen,Nathan, Clumeck,etc.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.[J].2006,43.
[33]Lopez R,Feldstein AE,Elgouhari HM,etc.An apoptosis panel for nonalcoholic steatohepatitis diagnosis.[J].2011,54(6).
[34]Garcia-Tsao, Guadalupe,Garra, Brian,Barr, Richard G.,etc.Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement[J].2015,276(3).
[35]Lee,J.-H.,Kim,D.,Kim,H.J.,etc.Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease[J].2010,42(7).
[36]Paul, Angulo,Jason M, Hui,Giulio, Marchesini,etc.The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.[J].2007,45.
[37]Rafiq N,Younossi ZM,Hossain N,etc.A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.[J].2011,21(4).
[38]Bril, Fernando,Barb, Diana,Lomonaco, Romina,etc.Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis[J].2020,72(3).
[39]Loomba, Rohit,Adams, Leon A..Advances in non-invasive assessment of hepatic fibrosis[J].2020,69(7).
[40]Grace Lai-Hung, Wong.Update of liver fibrosis and steatosis with transient elastography (Fibroscan).[J].2013,1.
[41]Barr, J.,Caballería, J.,Martínez-Arranz, I.,etc.Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression[J].2012,11(4).
[42]Verma,S.,Jensen,D.,Hart,J.,etc.Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)[J].2013,33(9).
[43]Attia, D.,Bantel, H.,Lenzen, H.,etc.Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients[J].2016,44(4).
[44]Patrick, Wainwright,Christopher D, Byrne.Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome.[J].2016.
[45]Cassinotto, Christophe,Feldis, Matthieu,Vergniol, Julien,etc.MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity[J].2015,84(8).
[46]Ankur Srivastava,Ruth Gailer,Sudeep Tanwar,etc.Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease[J].2019,71(2).
[47]Bahr,M.J.,Lichtinghagen,R.,Brand,K.,etc.The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values[J].2013,59(2).
[48].Non-invasive assessments for liver fibrosis - the crystal ball we long for.[J].2018,(Spec).
[49]Vincent Wai‐Sun Wong,Julien Vergniol,Grace Lai‐Hung Wong,etc.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease[J].2010,51(2).
[50]Vali, Yasaman,Lee, Jenny,Boursier, Jerome,etc.Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis[J].2020,73(2).
[51]Samuel J. Daniels,Diana J. Leeming,Mohammed Eslam,etc.ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis[J].2019,69(3).
[52]Cyrielle,Caussy,Justine,Brissot,Seema,Singh,etc.Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.[J].2019.
[53]Wai Janae Wentong,Fu Charmaine,Wong Vincent Wai-Sun.Confounding factors of non-invasive tests for nonalcoholic fatty liver disease[J].2020,55(8).
[54]Vincent Wai-Sun Wong,Marie Irles,Grace Lai-Hung Wong,etc.Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease[J].2019.
[55]Kenneth I,Zheng,Wen-Yue,Liu,Xiao-Yan,Pan,etc.Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels.[J].2020,8(1).
[56]Allen Alina M.,Shah Vijay H.,Therneau Terry M.,etc.The Role of Three‐Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery[J].2020,71(2).
[57]Hsu, Cynthia,Caussy, Cyrielle,Imajo, Kento,etc.Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants[J].2019,17(4).
[58]Musso,G.,Pagano,G.,Gambino,R.,etc.Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity[J].2011,43(7).
[59].Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients.[J].2017.
[60]Andrea,Dennis,Matt D,Kelly,Carolina,Fernandes,etc.Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis.[J].2020,11.